- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00990561
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
December 11, 2018 updated by: University of California, San Francisco
A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis
This is an investigator-masked, randomized, parallel, clinical study comparing the efficacy of once daily versus twice daily application of Ultravate® ointment (halobetasol propionate 0.05% ointment) in combination with Lac-Hydrin lotion (ammonium lactate topical) in the treatment of stable plaque psoriasis.
1) Phase 1: Patients will be treated for two weeks with combination therapy using Ultravate® ointment with Lac-Hydrin lotion and their psoriasis plaques will be evaluated to test efficacy of the medication.
Half the subjects will be randomized to receive treatment with once a day Ultravate® ointment and twice daily Lac-Hydrin lotion; the other half of subjects will receive twice daily Ultravate® ointment with twice daily Lac-Hydrin lotion.
Ultravate® ointment will be discontinued following two weeks of treatment, in compliance with its FDA indication.
Phase 2: The second treatment phase will consist of a four-week observation period.
Subjects will be re-randomized to either continue using twice daily Lac-Hydrin lotion, versus no treatment.
The purpose of this second phase of the study is to investigate whether use of Lac-Hydrin monotherapy twice daily can minimize risk of recurrence and maximize duration of therapeutic effect.
Part of this clinical study consists of the use of patient and physician satisfaction questionnaires.
These questionnaires will include questions about the satisfaction with the formulation of each agent, questions about compliance with treatment, etc.
Such questions could be used to demonstrate patient and physician satisfaction with each agent, with combination therapy, and to compare patient satisfaction rates among those randomized to once daily versus twice daily application of Ultravate® ointment.
The hypothesis is that Ultravate ointment once daily in combination with Lac-Hydrin twice daily is equal in efficacy to Ultravate ointment twice daily in combination with Lac-Hydrin twice daily.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94118
- UCSF Psoriasis and Skin Treatment Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinically diagnosed by an investigator to have stable plaque psoriasis with no more than 10% body surface area involvement.
- A subject must have an overall baseline score of 6 (moderate) or greater based on a twelve-point scale on the Psoriasis Severity Assessment (PSA) form. Elevation, erythema, and scale will each be graded on a four point scale with a maximum total of 12 points. Each of these 3 variables should be scored as at least a two. (Plaque elevation is defined as the total elevation, including adherent scales, relative to the surrounding skin).
- For female patients of childbearing potential, a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation).
- Negative urine pregnancy test at the time of study entry (for female patients of childbearing potential).
- Written, informed consent and photographic release.
- Ability to follow study instructions and likely to complete all required visits.
Exclusion Criteria:
- A female subject who is pregnant, nursing an infant or planning a pregnancy during the study (throughout the course of the study, women of childbearing potential must use reliable forms of contraception [i.e., abstinence, spermicides, condoms, or other reliable forms of contraception other than oral contraceptives].
- A subject with any uncontrolled systemic disease. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
- A subject with the presence of any skin disease that might interfere with the diagnosis or evaluation of the test medications.
- A subject that has a condition or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
- A subject with spontaneously improving or rapidly deteriorating plaque psoriasis.
- A subject with pustular or erythrodermic psoriasis.
- A subject diagnosed by an investigator to have stable plaque psoriasis involvement that exceeds more than 10% of the subject's body surface area.
- Use of systemic agents such as oral retinoids, methotrexate, cyclosporine or systemic corticosteroids within four weeks prior to study entry.
- Use of biologic agents such as alefacept, infliximab, efalizumab, adalimumab, or etanercept within four weeks prior to study entry.
- Use of topical drugs that might alter the course of psoriasis (e.g., corticosteroids, retinoids, vitamin D analogues, salicylic acid, tacrolimus, tar and anthralin,) or has received Ultraviolet B treatment within two weeks prior to study entry.
- Use of phototherapy with psoralen ultraviolet A treatment within four weeks prior to study entry.
- A subject with a known sensitivity to any of the study treatments and/or their components.
- A subject who will require excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) during the study.
- A subject who anticipates a need to use other topical or systemic therapy that might alter the course of psoriasis.
- A subject who anticipates the need for surgery or hospitalization during the study.
- Concurrent involvement in any other clinical study with an investigational drug or device, or participation in a clinical study within 30 days prior to entering the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Twice Daily Ultravate
Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
|
Topical corticosteroid
Other Names:
|
Active Comparator: Once daily Ultravate
Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
|
Topical corticosteroid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Modified Psoriasis Area Severity Index (PASI) Score
Time Frame: 2 weeks
|
PASI is a scale that measures psoriasis severity based on erythema, induration, scaling, and body surface area covered.
It ranges from 0 (no disease) to 72 (most extensive).
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Tina Bhutani, MD, UCSF Clinical Fellow
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
October 5, 2009
First Submitted That Met QC Criteria
October 6, 2009
First Posted (Estimate)
October 7, 2009
Study Record Updates
Last Update Posted (Actual)
January 4, 2019
Last Update Submitted That Met QC Criteria
December 11, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ultravate Lac-Hydrin Ranbaxy
- H5939-34434-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stable Plaque Psoriasis
-
LEO PharmaCompleted
-
Promius Pharma, LLCCompletedChronic Stable Plaque PsoriasisUnited States
-
Innovation Pharmaceuticals, Inc.CompletedChronic Stable Plaque PsoriasisUnited States
-
SandozHexal AGCompletedChronic Stable Plaque PsoriasisGermany, Romania, Bulgaria, Czech Republic, Estonia, Hungary, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
-
University of California, San FranciscoCompletedChronic Stable Plaque PsoriasisUnited States
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
Clinical Trials on Ultravate ointment twice daily + LacHydrin lotion twice daily
-
Galderma R&DCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Manal AbdelmalekCompletedNonalcoholic SteatohepatitisUnited States
-
Spectrum Pharmaceuticals, IncTerminated
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Unity Health TorontoCompleted
-
Case Western Reserve UniversityNational Institute of Nursing Research (NINR); MetroHealth Medical CenterCompletedCritical IllnessUnited States
-
National Cancer Institute, EgyptUnknownBreast Cancer | Radiation ToxicityEgypt
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedAtopic DermatitisUnited States